Un­der pres­sure to per­form, Wood­ford coun­ter­at­tacks against Sahm Ad­rangi's lat­est short as­sault

Feel­ing the heat now on his strug­gling funds, Neil Wood­ford has come out swing­ing against Sahm Ad­ran­gi and Ker­ris­dale Cap­i­tal, which re­cent­ly slammed one of his big biotech bets.

At an event in Lon­don, Wood­ford went on the at­tack against Ad­ran­gi, who bad­ly dam­aged Prothena $PR­TA with a blis­ter­ing at­tack on its lead drug, NEOD001, an AL amy­loi­do­sis drug.

Ac­cord­ing to Ker­ris­dale an­a­lysts, the Phase I/II study for this drug failed to show any promise. Point­ing to ex­pert — though un­named — fig­ures in the field, the da­ta from the loom­ing Phase IIb and Phase III stud­ies will prove the drug’s worth­less­ness be­yond any doubt.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER